The first fund for investing in early-stage businesses has been launched by IXP, a Life Sciences venture capital firm supported by JV Ventures. The fund seeks to assemble a portfolio of business-to-business (B2B) firms in pre-seed and Series A stages.
The IXP Lifesciences Catalyst Fund has a greenshoe option of Rs 100 crore and aims to reach a corpus of Rs 200 crore. The fund intends to build a portfolio of 20–25 businesses that fill goods and service gaps in the market. The fund will make investments in life sciences innovations in fields like pharmaceuticals, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals.
It will collaborate with scientists to co-create businesses through IXP Venture Studio in order to develop concepts that meet unmet market demands. It adopts a hands-on strategy, actively participating from concept to scale, in contrast to traditional VCs. The goal of the Venturepreneur Program is to turn scientists into entrepreneurs.
IXP claims that early-stage businesses need access to more extensive ecosystems, such as labs, networks, and R&D services, which it offers through PoweRx, JV Ventures’ Life Sciences vertical. The venture capital firm uses group synergies to develop a compelling offer for portfolio companies.
By incorporating scientists and innovators into a vibrant life sciences ecosystem, IXP (Innovation Acceleration Platform) seeks to assist them in their entrepreneurial endeavors. In order to help bring innovative ideas to market, the venture capital firm highlights that it is composed of a strong team and is aware of the lengthy gestation periods and capital-intensive nature of research and development.
